Inactive Instrument

Biondvax Pharmaceuticals Ltd Share Price Other OTC

Equities

Duration

Period

Style

Biondvax Pharmaceuticals : Announces Rights Offering Fully Subscribed at US$20 Million	16/07/19	PU
Biondvax Pharmaceuticals : First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial	08/07/19	PU
Biondvax Pharmaceuticals : European Investment Bank VP attends Signature Event at BiondVax Extending Financing Agreement with BiondVax to €24 million	26/06/19	PU
Biondvax Pharmaceuticals : Patent Covering Manufacturing Process of BiondVax’s M-001 Universal Flu Vaccine Allowed in USA and Japan	18/06/19	PU
Biondvax Pharmaceuticals : Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process	10/06/19	PU

Managers	Title	Age	Since
Amir Reichman CEO	Chief Executive Officer	49	01/03/21
Uri Ben-Or DFI	Director of Finance/CFO	52	31/12/06
Dalit Weinstein Fischer CTO	Chief Tech/Sci/R&D Officer	-	31/12/21

Members of the board	Title	Age	Since
Adi Raviv BRD	Director/Board Member	69	23/03/20
Samuel Moed BRD	Director/Board Member	62	23/03/20
Morris Laster BRD	Director/Board Member	60	26/11/17

Sector

	1st Jan change	Capi.
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+46.56%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B